Current Immunotherapy Progress in the Hodgkin Lymphoma
DOI:
https://doi.org/10.54097/kxh08k74Keywords:
Hodgkin lymphoma; Immunotherapy; Lymphatic system; Checkpoint inhibitors; Monoclonal antibodies.Abstract
Hodgkin lymphoma, a distinctive cancer affecting the lymphatic system, poses challenges in treatment due to its unique characteristics and the limitations of traditional therapies. This essay delves into the potential of immunotherapy to transform the landscape of treatment for Hodgkin lymphoma. Furthermore, the essay analyses case studies to illustrate the efficacy of these approaches. It presents an overview of the underlying principles, as well as specific immunotherapeutic approaches, such as checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapy, and their mechanisms. Immunotherapy offers a targeted and personalized alternative to conventional chemotherapy and radiation, presenting promising results in clinical trials. Clinicians manage subtleties in immune-related toxicity and response assessment as the field develops. The goal of immunotherapy research in the initial phases of treatment is to increase cure rates while lowering long-term dangers. Ongoing research and advancements, including checkpoint blockade studies, offer hope for refining treatment approaches and optimizing outcomes in Hodgkin lymphoma. This essay emphasizes the significance of immunotherapy in providing effective and less toxic alternatives, heralding a new era in Hodgkin lymphoma treatment.
Downloads
References
Diehl, V., Thomas, R. K. & Re, D. Part II: Hodgkin’s lymphoma—diagnosis and treatment. The Lancet Oncology 5, 19–26 (2004).
Diehl, V. Dose-escalation study for the treatment of Hodgkin’s disease. Annals of Hematology 66, 139–140 (1993).
Schilsky, R. L. et al. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin’s disease. The American Journal of Medicine 71, 552–556 (1981).
Aleman, B. M. P. et al. Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease. Journal of Clinical Oncology 21, 3431–3439 (2003).
Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine 8, (2016).
Roemer, M. G. et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Blood 126, 176–176 (2015).
Ansell, S. M. et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. New England Journal of Medicine 372, 311–319 (2015).
Pathak, N. et al. Modified Protocol of Nivolumab in Relapsed/Refractory Hodgkin Lymphoma: A Brief Communication of Real-World Data. Journal of Immunotherapy 45, 239–242 (2022).
Armand, P. et al. Programmed Death-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. Journal of Clinical Oncology 34, 3733–3739 (2016).
Diefenbach, C. S. et al. Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). Blood 126, 585–585 (2015).
Younes, A. et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin’s Lymphoma. Journal of Clinical Oncology 30, 2183–2189 (2012).
Straus, D. J. et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 135, 735–742 (2020).
Kasamon, Y. L. et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 119, 4129–4132 (2012).
Ramos, C. A. et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. Journal of Clinical Oncology 38, 3794–3804 (2020).
Bair, S. M., Mato, A. & Svoboda, J. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm. Clinical Lymphoma Myeloma and Leukemia 18, 380–391 (2018).
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
